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The prevalence of obesity and its associated 
metabolic complications has dramatically 
increased during the past decades; it has been 
suggested that this could, to some extent, be 
linked to the exposure to environmental pol­
lutants, which coincidently increased during 
the same period (Baillie­Hamilton 2002; Grun 
and Blumberg 2007; Heindel 2003; Newbold 
et al. 2007). Endocrine disruptors constitute a 
wide class of chemicals that can affect human 
and animal populations by interfering with 
the synthesis, elimination, and mechanisms 
of action of hormones (Markey et al. 2002; 
Waring and Harris 2005). One of their key 
mechanisms of action is the modulation of 
gene expression programs by targeting the 
activity of a family of nuclear receptors that are 
activated by intracellular lipophilic hormones 
and mediators. The concept of endocrine dis­
ruption, which initially arose because of the 
interference with reproductive biology, is now 
gradually being broadened to other receptors 
implicated in different aspects of homeostasis 
(Tabb and Blumberg 2006).
Metabolic homeostasis requires a controlled 
balance between energy storage and use, and 
several nuclear receptors as well as their coregu­
lators are instrumental in regulating these pro­
cesses (Desvergne et al. 2006; Feige and Auwerx 
2007). Among these, peroxisome proliferator–
activated receptors (PPARs) play a prominent 
role by acting as lipid sensors that cooperate 
in different organs to adapt gene expression 
to a given metabolic status (Desvergne et al. 
2004; Evans et al. 2004; Feige et al. 2006). 
PPARα (NR1C1) is the founding member 
of the family and was initially isolated as the 
receptor inducing the hepatic proliferation of 
peroxisomes in rodents in response to synthetic 
chemicals. However, this function represents 
only a small subset of the physiologic func­
tions regulated by this receptor. PPARα and 
PPARβ/δ (NR1C2, referred to here as PPARβ) 
share partially overlapping functions in the con­
trol of catabolic metabolism by promoting fatty 
acid oxidation in tissues with high metabolic 
rates such as liver or muscle (Desvergne et al. 
2004; Evans et al. 2004; Feige et al. 2006). In 
contrast, PPARγ (NR1C3) controls fat storage 
in adipose tissue by promoting differentiation 
and survival of adipocytes and also plays major 
roles in the control of insulin sensitivity (Lehrke 
and Lazar 2005).
Several endocrine disruptors, including pes­
ticides, industrial solvents, and plasticizers, can 
activate PPARs in cellular models (Bility et al. 
2004; Grun et al. 2006; Hurst and Waxman 
2003; Kanayama et al. 2005; Lapinskas et al. 
2005; Takeuchi et al. 2006). However, the 
metabolic consequences of PPAR activation by 
endocrine disruptors remain largely unknown, 
although some physiologic consequences are 
emerging, such as adipogenic action of organo­
tins (Grun et al. 2006) and PPARα­dependent 
induction of hepatic peroxisome proliferation 
by phthalates (Lapinskas et al. 2005; Ward 
et al. 1998). Diethylhexyl phthalate (DEHP) 
is among the phthalate esters most abundantly 
used as industrial plasticizers and is also found 
in cosmetics, as well as in industrial paints and 
solvents. DEHP is found in flexible plastics 
used for manufacturing a wide variety of daily 
products, including medical devices and food 
packaging, and its propensity to leach can lead 
to high levels of human exposure [National 
Toxicology Program Center for the Evaluation 
of Risks to Human Reproduction (NTP­
CERHR) 2000]. When ingested through 
contaminated food, DEHP is converted by 
intestinal lipases to its monoester equivalent 
monoethylhexyl phthalate (MEHP), which 
is then preferentially absorbed (Huber et al. 
1996). MEHP can then be metabolized into 
a myriad of secondary metabolites that can be 
excreted (Rusyn et al. 2006), among which 
2­ethylhexanoic acid has also been reported as a 
low­affinity PPARα activator (Lapinskas et al. 
2005; Maloney and Waxman 1999). The bio­
logical effects of exposure to DEHP are hence 
of major concern, but their possible adverse 
effects on human health remain obscure.
These observations led us to investigate 
the molecular aspects of phthalate­mediated 
activation of PPARγ. In cellular models, 
MEHP induces adipo  genesis by modulating 
PPARγ activity (Feige et al. 2007), suggesting 
that DEHP could promote obesity in vivo if 
its MEHP metabolite reaches adipose tissue 
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Ba c k g r o u n d: The modulation of energetic homeostasis by pollutants has recently emerged as 
a potential contributor to the onset of metabolic disorders. Diethylhexyl phthalate (DEHP) is a 
widely used industrial plasticizer to which humans are widely exposed. Phthalates can activate the 
three peroxisome proliferator–activated receptor (PPAR) isotypes on cellu  lar models and induce 
peroxisome proliferation in rodents. 
oBjectives: In this study, we aimed to evaluate the systemic and metabolic consequences of DEHP 
exposure that have remained so far unexplored and to charac  terize the under  lying molecular mecha-
nisms of action. 
Me t h o d s : As a proof of concept and mechanism, genetically engineered mouse models of PPARs 
were exposed to high doses of DEHP, followed by metabolic and molecular analyses. 
re s u l t s: DEHP-treated mice were protected from diet-induced obesity via PPARα-dependent 
activation of hepatic fatty acid catabolism, whereas the activity of neither PPARβ nor PPARγ was 
affected. However, the lean phenotype observed in response to DEHP in wild-type mice was sur-
prisingly abolished in PPARα-humanized mice. These species differences are associated with a dif-
ferent pattern of coregulator recruitment. 
co n c l u s i o n: These results demonstrate that DEHP exerts species-specific metabolic actions that 
rely to a large extent on PPARα signaling and highlight the metabolic importance of the species-
specific activation of PPARα by xenobiotic compounds.
key w o r d s : DEHP, endocrine disruptor, metabolism, PPAR, species specificity. Environ Health 
Perspect 118:234–241 (2010).  doi:10.1289/ehp.0901217 available via http://dx.doi.org/ [Online 
8 October 2009]DEHP affects obesity in vivo
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(Grun and Blumberg 2007; Heindel 2003). 
However, MEHP also activates PPARα and 
PPARβ in vitro (Bility et al. 2004; Feige et al. 
2007; Hurst and Waxman 2003; Lapinskas 
et al. 2005), suggesting that DEHP expo­
sure may also promote fatty acid oxidation. 
In the present study, we addressed the meta­
bolic consequences of DEHP exposure in mice. 
Intriguingly, DEHP exposure protected mice 
from weight gain under both a regular diet and 
a diet containing high fat content; this effect 
could be attributed solely to the hepatic oxida­
tive functions of PPARα. The lean phenotype 
of DEHP­treated mice was not observed in 
mice humanized for PPARα where the mouse 
receptor has been replaced by a human PPARα 
(hPPARα) transgene. At the molecu  lar level, the 
functional differences between mouse PPARα 
(mPPARα) and hPPARα are associated with a 
different pattern of coregulator recruitment in 
the presence of MEHP. Altogether, our obser­
vations highlight key physiopathologic con­
sequences of chronic exposure to DEHP and 
highlight the metabolic importance of the spe­
cies­specific metabolic consequences of PPARα 
activation by xenobiotics compounds.
Materials and Methods
Animal experiments. We carried out DEHP 
exposure in wild­type (WT) mice using 
C57Bl6J mice (Charles River, L’Arbresle, 
France), which were fed a chow diet (CD) 
or a high­fat diet (HFD) containing 60% fat 
(Provimi­Kliba, Kaiseraugst, Switzerland), sup­
plemented with 10 mL sunflower oil (vehicle) 
per kilogram of feed in the presence or absence 
of DEHP (Sigma Aldrich, Buchs, Switzerland). 
Genetically engineered mouse models are 
described in the Supplemental Material avail­
able online (doi:10.1289/ehp.0901217.S1 via 
http://dx.doi.org/). Animal experiments were 
conducted humanely and with regard for alle­
viation of suffering, and were approved by the 
relevant animal welfare commissions.
Metabolic phenotyping. We performed 
glucose tolerance tests after an intraperitoneal 
injection of 2 g glucose/kg body mass after 
4 hr of fasting. Fat and lean body composi­
tions were measured by nuclear magnetic 
resonance (NMR) on an Echo­MRI (mag­
netic resonance imaging) 100 apparatus 
(Echo Medical Systems, Houston, TX, USA). 
Indirect calorimetry in metabolic cages was 
performed with a Comprehensive Lab Animal 
Monitoring System (Columbus Instruments, 
Columbus, OH, USA) during 24 hr after a 
36­ to 48­hr acclimation period. The exercise 
test was performed on a treadmill (Columbus 
Instruments); a 6­min training period at low 
velocity was given 24 hr before the exercise 
(Feige et al. 2008; Lagouge et al. 2006). Mice 
were exercised until they reached fatigue 
[defined by resting for > 50% of the time on 
the shock pad; see Supplemental Material, 
Figure 2 (doi:10.1289/ehp.0901217.S1)]. 
Biochemical assays and quantitative PCR (poly­
merase chain reaction) techniques are described 
in the Supplemental Material (doi:10.1289/
ehp.0901217.S1).
Reporter gene and pull-down assays. We 
performed PPAR luciferase­based reporter 
gene assays in C2C12 mouse myoblast cells 
using plasmids, compounds, and procedures 
described previously (Feige et al. 2005, 2007). 
Pull­downs using glutathione S­transferase 
(GST)­labeled coregulators and 35S­labeled 
PPARα produced in reticulocyte lysates were 
performed as described previously (Feige et al. 
2005, 2007) in the presence of vehicle, 100 µM 
Wy14643 (Cayman Chemicals, Ann Harbor, 
MI, USA), or 1,000 µM MEHP (Imperial 
Chemical Industries, Slough, UK). The pri­
mary culture of hepatocytes and adenoviral 
infections are described in the Supplemental 
Materials (doi:10.1289/ehp.0901217.S1).
Statistical analyses. All data are reported 
as mean ± SE. Results were considered statis­
tically significant when p­values were < 0.05 
by unpaired two­tailed Student’s t­test. 
Results
DEHP exposure protects from obesity in mice. 
The ability of the DEHP metabolite MEHP 
to activate PPARα and PPARβ, on the one 
hand, and PPARγ on the other, suggests that 
this endocrine disruptor could potentially 
influence the two arms of the energetic bal­
ance by affecting both energy expenditure 
and storage. To understand the global meta­
bolic output of an exposure to DEHP, we 
fed WT C57Bl6J mice with a regular CD 
containing vehicle or DEHP. Animals were 
thereby exposed to the compound through 
intestinal absorption, a route that mimics one 
of the most frequent sources of exposure in 
humans and favors the conversion of DEHP 
to its major bioactive metabolite MEHP. 
DEHP was incorporated in the diet at two 
concentrations, leading to average exposures 
of 100 and 1,000 mg/kg body mass/day), dos­
ages that were previously reported to be less 
than and greater than the minimal exposure 
required for hepatic peroxisome proliferation, 
respectively (David et al. 1999). The treatment 
started just after weaning at 3 weeks of age. 
At week 13, mice treated with 1,000 mg/kg/
day DEHP gained approximately 15% less 
weight than did controls or mice treated with 
100 mg/kg/day; this difference did not result 
from different feeding behaviors because all 
three groups consumed the same amount of 
food (Figure 1A). Consistently, the lean mass 
meas  ured by NMR was not affected by the 
treatment at either dose, but the weight dif­
ference at the high dose was solely caused by 
reduced total body fat (Figure 1B). Along the 
same line, the mass of the epididymal white 
adipose tissue (epiWAT) at sacrifice was 
Figure 1. DEHP exposure induces a lean phenotype in WT mice on CD. Four-week-old WT C57Bl6J male 
mice were fed a CD supplemented with vehicle (10 mL/kg feed) alone or combined with DEHP for an 
exposure of either 100 or 1,000 mg/kg/day (n = 10/group). (A) Body mass after 13 weeks of treatment 
and average weekly food intake during the treatment period. (B) Body composition measured by MRI at 
the beginning and at the end of the treatment. (C) epiWAT and liver mass after 13 weeks of treatment. 
(D) Plasma profile after 13 weeks of treatment. OD, optical density.
*p ≤ 0.05 compared with vehicle treatment. 
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also reduced by 40% (Figure 1C). Only the 
high dose of DEHP induced a hepatomegaly 
(Figure 1C), testifying that significant per­
oxisome and hepatocyte proliferation occurred 
only at 1,000 mg/kg/day (Rusyn et al. 2006). 
In the blood, triglyceride and free fatty acid 
levels were reduced in DEHP­treated mice 
(Figure 1D), suggesting that the reduced fat 
mass of these animals reflects enhanced fatty 
acid oxidation. DEHP treatment consistently 
increased plasma total ketone bodies, a marker 
of hepatic fatty acid oxidation. Plasma glu­
cose levels were not affected by DEHP in fed 
or fasted animals (Figure 1D and data not 
shown, respectively). Although DEHP treat­
ment did not modify glucose tolerance [see 
Supplemental Material, Figure 1 (doi:10.1289/
ehp.0901217.S1)], insulin levels were signifi­
cantly lower in mice treated with 1,000 mg/
kg/day DEHP (Figure 1D). Altogether, these 
results demonstrate that DEHP exposure 
reduces adiposity under CD.
To understand whether a diet high in fat 
would exacerbate or counterbalance this lean 
phenotype, we fed adult WT mice the HFD 
(containing 60% calories as fat) supple­
mented with vehicle or 500 mg/kg/day DEHP 
(Figure 2). The HFD alone led to a doubling 
of body mass (Figure 2A), essentially due to the 
increased fat mass from 8–10% of body mass 
before treatment (as measured by NMR), to 
30% after 13 weeks of HFD, whereas fat mass 
remained at 8–10% after 13 weeks of CD (data 
not shown). DEHP strongly protected mice 
from HFD­induced obesity without affecting 
food intake (Figure 2A). Although hepato­
megaly was observed in DEHP­treated mice 
because of PPARα­dependent peroxisome and 
hepatocyte proliferation (Rusyn et al. 2006), 
in vivo analyses of body composition revealed 
that the reduced body mass resulted from 
lower fat mass (Figure 2B,C). Consistent with 
its protective effect on adiposity, DEHP inhib­
ited adipocyte hyper  trophy and hepatic lipid 
droplet accumulation (Figure 2D). Despite 
peroxisome proliferation in hepatocytes in 
response to DEHP, the global histology of 
the liver was normal, with no signs of inflam­
mation or necrosis (Figure 2D). The normal 
plasma levels of alanine aminotransferase and 
aspartate aminotransferase (Figure 2E), two 
markers of liver damage, further suggest that 
the lean phenotype of DEHP­treated mice is 
not the consequence of hepatic toxicity. In 
addition, the reduced adiposity did not result 
from a difference in lipid absorption or excre­
tion, because lipid concentrations in the feces 
were not affected by the treatment (Figure 2F). 
DEHP exposure did not affect free fatty acid 
levels but significantly reduced triglyceride and 
increased ketone body concentrations, thereby 
suggesting a catabolic state primarily occurring 
in the liver (Figure 2G). As observed under 
the CD, insulin levels were also reduced in the 
blood of DEHP­treated animals, whereas gly­
cemia was not affected.
Metabolic phenotyping of DEHP-treated 
mice. Indirect calorimetry revealed that 
DEHP treatment increases oxygen consump­
tion and carbon dioxide release both during 
day and night (Figure 3A), thus providing 
evidence of an increased metabolic rate in 
DEHP­treated mice. However, the fuel pref­
erence was not modified by the exposure 
to DEHP because the respiratory exchange 
ratio [ratio between carbon dioxide (CO2) 
release and oxygen (O2) consumption] was 
not affected. Although the protective effect of 
DEHP on body weight gain was not a con­
sequence of increased spontaneous locomo­
tor activity (Figure 3A), we evaluated muscle 
functions by an exercise test that evaluates the 
global oxidative capacities of skeletal muscle. 
The distance ran until fatigue did not differ 
between DEHP­treated mice and their con­
trols (Figure 3B), indicating that muscle is 
not the primary site of MEHP action.
Figure 2. DEHP exposure induces a lean phenotype in WT mice on an HFD. Seven-week-old WT C57Bl6J male mice were fed HFD supplemented with vehicle 
(10 mL/kg feed) alone or combined with DEHP for an exposure of 500 mg/kg/day (n = 9/group). Abbreviations: ALAT, alanine aminotransferase; ASAT, aspar-
tate amino  transferase; FFA, free fatty acids; ND, not detected; TG, triglycerides. (A) Growth curve and average weekly food intake during the entire treatment. 
(B) Body composition measured by MRI after 13 weeks of treatment. (C) epiWAT and liver mass at the end of the treatment period. (D) epiWAT (top) and liver 
(bottom) histology at the end of the treatment. (E) Plasma levels of ASAT and ALAT at the end of the treatment period. (F) Lipid and cholesterol levels in feces. 
(G) Plasma profiles of TG, FFA, glucose, insulin, and ketone bodies at the end of the treatment period.
*p ≤ 0.05 compared with vehicle treatment. 
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The active DEHP metabolite MEHP can 
activate the three PPAR isotypes, of which 
PPARγ plays a crucial role in controlling insu­
lin sensitivity (Lehrke and Lazar 2005). A full 
PPARγ activation seems unlikely in DEHP­
treated mice because PPARγ activation by full 
agonists such as thiazolidinediones promotes 
adipogenesis and weight gain. However, we 
recently reported that MEHP acts as a selective 
PPARγ modulator (Feige et al. 2007), a class of 
compounds capable of uncoupling the action 
of PPARγ on adipogenesis from those on insu­
lin sensitivity and glucose tolerance (Gelman 
et al. 2007). We therefore meas  ured glucose 
tolerance and found that DEHP admin­
istration mildly enhanced glucose tolerance 
(Figure 3C). However, given the detrimental 
action of adiposity on glucose tolerance, this 
effect is most likely a consequence of the lean 
phenotype rather than of PPARγ activation.
DEHP activates hepatic fatty acid oxida-
tion through PPARα. One key question to 
fully understand the metabolic consequences 
of DEHP exposure is the individual responses 
of organs controlling energy expenditure and 
storage. Because MEHP can activate the three 
PPAR isotypes in cellular systems, all PPAR­
expressing tissues are potential targets if they 
are exposed to MEHP upon DEHP inges­
tion. We thus measured the expression of well­
characterized PPAR target genes (Figure 4). In 
the liver, DEHP exposure induced the expres­
sion of genes implicated in various aspects of 
fatty acid oxidation, including mitochondrial 
β­oxidation (medium chain acylCoA dehy­
drogenase; MCAD), peroxisomal β­oxidation 
(AcylCoA oxidase 1; ACOX), intracellular fatty 
acid shuttling (fatty acid binding protein 1; 
FABP-1), and mitochondrial fatty acid import 
(carnitine palmitoyl transferase 1a; CPT-1a) 
(Figure 4A). Strikingly, DEHP also robustly 
induced the hepatic expression of fibroblast 
growth factor 21 (FGF-21), a gene recently 
described to control lipid oxidation and keto­
genesis in the liver and lipolysis in the adipose 
tissue (Badman et al. 2007; Inagaki et al. 2007; 
Kharitonenkov et al. 2005). These gene profil­
ing experiments were functionally confirmed 
by the biochemical measurement of hepatic 
hydroxyacyl­CoA dehydrogenase activity, 
which demon  strated that fatty acid oxidation 
was increased in the liver of DEHP­treated 
mice (Figure 4E). Because PPARα is the most 
prominent hepatic PPAR isotype and all five 
of the genes we tested are reported to be under 
the direct transcriptional control of PPARα, 
these observations suggested that the lean phe­
notype of DEHP­treated mice results at least in 
part from hepatic fatty acid oxidation mediated 
by PPARα. Other energy­dissipating tissues 
expressing PPARs do not seem to contribute 
to this phenotype as oxidative target genes in 
skeletal muscle [long chain acyl­CoA dehydro­
genase (LCAD) and pyruvate dehydrogenase 
kinase 4 (PDK4)] and in brown adipose tissue 
[uncoupling protein 1 (UCP1) and PPARγ 
coactivator 1α (PGC-1α)] were not affected 
(Figure 4B,D). In addition, the expression of 
adipogenic target genes under direct transcrip­
tional control of PPARγ in white adipose tissue 
(WAT) was not affected (Figure 4C). These 
gene expression data therefore demonstrate 
that DEHP exposure does not affect adipo­
genesis in vivo and drives a catabolic response 
occurring primarily in the liver, most probably 
through activation of PPARα.
Figure 4. DEHP promotes hepatic fatty acid oxidation. Gene expression was determined by quantita-
tive reverse transcriptase-PCR [see Supplemental Material (doi:10.1289/ehp.0901217.S1) for details] on 
RNA extracted from liver (A), gastrocnemius skeletal muscle (B), epiWAT (C), and brown adipose tissue 
(BAT) (D). Gene expression was normalized to three housekeeping genes (glyceraldehyde-3-phosphate 
dehydrogenase, β glucuronidase, and ribosomal protein S9 for the liver; eukaryotic translation elonga-
tion factor 1α1, TATA box binding protein, and ribosomal protein S9 for the other tissues). Abbreviations: 
ACOX, acyl-CoA oxidase 1; ACS-1, acetyl-CoA synthetase 1; AdipoQ, adiponectin; CPT-1a, carnitine palmi-
toyltransferase 1a (liver); FABP-1, fatty acid binding protein 1 (liver); FABP-4/aP2, fatty acid binding protein 
4 (adipocyte); FATP-1, fatty acid transport protein 1; FGF-21, fibroblast growth factor 21; LCAD, long chain 
acyl-CoA dehydrogenase; MCAD, medium chain acyl-CoA dehydrogenase; PDK4, pyruvate dehydrogenase 
kinase 4; PGC-1α, PPARγ coactivator 1α; UCP1, uncoupling protein 1. (E) 3-Hydroxyacyl-coenzyme A dehy-
drogenase (HAD) activity was measured in liver extracts of DEHP-treated mice given the HFD. 
*p ≤ 0.05 compared with vehicle treatment. 
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Because the oxidative functions of PPARα 
and PPARβ partially overlap, we dissected 
the contribution of each individual recep­
tor by feeding PPARα­ and PPARβ­null 
mice the HFD supplemented with DEHP. 
We observed the protective effects of DEHP 
on weight gain in WT mice as well as in 
PPARβ­null mice (Figure 5A,B). In contrast, 
DEHP did not influence the body mass of 
PPARα­null mice (Figure 5A), demonstrat­
ing that the anti­obesity action of DEHP 
requires PPARα only. This conclusion was 
further corroborated by reduced fat mass after 
DEHP exposure in PPARβ­null mice but not 
PPARα­null mice (Figure 5C–F). Similarly, 
the DEHP­dependent hepatomegaly caused 
by peroxisome proliferation was PPARα­ but 
not PPARβ­dependent (Figure 5E,F). PPARα 
was also indispensable to the hepatic induc­
tion of oxidative gene expression after DEHP 
exposure (Figure 5G), whereas the influence 
of PPARβ was modest to non  existent based 
on the genes analyzed (Figure 5H). To fur­
ther demon  strate the role of hepatic PPARα 
in the response to DEHP, we isolated primary 
hepatocytes from WT and PPARα­null mice 
and showed that only WT hepatocytes were 
responsive to MEHP. In addition, the lack of 
response to MEHP in PPARα­null hepato­
cytes was restored by adenoviral­mediated over­
expression of PPARα (Figure 5I). Altogether, 
these results demonstrate that DEHP protects 
from obesity by activating the catabolic func­
tions of PPARα in the liver.
DEHP protects WT mice but not human-
ized models from obesity. The identification of 
hepatic PPARα­dependent activation as the 
cause of the lean phenotype of DEHP­treated 
mice raises the question of how this protective 
action may translate to humans exposed to 
DEHP. In mice, peroxisome and hepatic prolif­
eration is directly controlled by PPARα activa­
tion and coexists with metabolic actions of the 
receptor on fatty acid oxidation, whereas only 
the actions on fatty acid oxidation extend to 
humans. To overcome this dual role of PPARα 
in mice, we analyzed the action of DEHP on 
HFD in a humanized mouse model of PPARα 
that is insensitive to hepatocellular proliferation 
(Yang et al. 2008). In this model, the entire 
human PPARα gene and its regulatory regions 
were introduced into the mPPARα null back­
ground, thereby allowing the expression, reg­
ulation, and function of human PPARα in 
the mouse. Although DEHP limited weight 
gain in WT mice as shown above, PPARα­
humanized mice were not protected against 
diet­induced obesity (Figure 6A), demon­
strating that this beneficial effect is limited to 
mPPARα activation. Indeed, and as expected, 
humanized PPARα mice did not develop 
the DEHP­induced hepatomegaly caused by 
cell proliferation (Figure 6B), but presented a 
slight excess of adiposity upon DEHP expo­
sure. This was evidenced by an increase in total 
body mass and in epiWAT (Figure 6A,B). We 
thus evaluated gene expression in the liver and 
WAT to understand how DEHP may promote 
fat accumulation in humanized PPARα mice. 
Strikingly, although this PPARα­humanized 
mice model can respond to a classic PPARα 
agonist (Yang et al. 2008), we observed no 
activation of the genes and enzymatic activities 
controlling hepatic β­oxidation in response to 
DEHP (Figure 6C,D). The fact that DEHP­
treated PPARα­humanized mice gained more 
weight than did their untreated counterparts 
was furthermore not caused by enhanced 
adipo  genesis and fat storage via PPARγ acti­
vation in WAT because the expression of 
direct adipogenic PPARγ target genes was not 
modified (data not shown). Altogether, these 
results demon  strate that the protective effects 
of DEHP on weight gain are dependent on the 
species origin of the PPARα receptor and most 
probably do not extend to humans, in which 
Figure 5. The lean phenotype of DEHP-treated mice requires PPARα but not PPARβ. PPARα (α) WT and 
null [knockout (KO)] mice on a pure SV129 background (A, C, E, G) and PPARβ (β) WT and KO mice on a 
mixed SV129/C57Bl6J background (B, D, F, H) were fed HFD and exposed to vehicle or 500 mg/kg DEHP as 
described in Figure 2 (n = 6/group). Body mass (BM; A, B) and body composition measured by MRI (C, D) 
were measured after 13 weeks of treatment. At the end of the treatment period, epiWAT and liver masses 
were analyzed (E, F), and liver gene expression was measured (G, H) as described in Figure 4. (I) Fold induc-
tion of FGF-21 mRNA meas  ured in primary hepatocytes derived from PPARα WT and KO mice, infected with 
adeno  viruses (Ad) encoding green fluorescent protein (GFP) or mouse PPARα adenoviruses and treated 
with 100 µM MEHP for 12 hr. 
*p ≤ 0.05 compared with vehicle treatment. 
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the metabolic consequences of DEHP expo­
sure, if any, should rather be detrimental.
According to the humanized mouse model 
used in this study, the mechanism involved in 
the species­specific response to DEHP seems 
to rely solely on differences in the receptor 
itself. To understand the molecular basis of 
this differential action, we first evaluated the 
ability of mPPARα and hPPARα to activate 
the PPAR response element of a reporter con­
struct in the presence of the full PPAR agonist 
Wy14643 or of MEHP, the active metabolite 
of DEHP (Figure 7A). In this assay, MEHP 
treatment resulted in a maximal activation of 
mPPARα and hPPARα to a similar extent, 
despite having a slightly higher affinity for 
the mouse than for the human receptor, as 
previously observed (Bility et al. 2004; Hurst 
and Waxman 2003). To further analyze what 
could be the functional consequence of the 
subtle conformational differences of mPPARα 
versus hPPARα, we tested their ability to inter­
act with coregulators in the absence of ligand 
or upon binding of Wy14643 or MEHP 
(Figure 7B). In the presence of Wy14643, 
mPPARα and hPPARα shared a similar pat­
tern of interaction with coregulators, releasing 
NCoR (nuclear receptor co­repressor 1) and 
efficiently recruiting Med1 (mediator complex 
subunit 1), PGC­1α (peroxisome proliferator­
activated receptor­γ coactivator 1α), and to 
a lower extent p300 (E1A binding protein 
p300). In contrast, MEHP induced a partial 
release of NCoR with both the mouse and 
the human receptor but failed to induce the 
ligand­dependent recruitment of the coactiva­
tors Med1, p300, and PGC­1α to mPPARα. 
In contrast, all three coactivators were effi­
ciently recruited by the human receptor in 
the presence of MEHP, at a level very close to 
that obtained with Wy14643. Together with 
the experiments in the humanized PPARα 
mouse model, these in vitro observations sug­
gest that subtle differences in the mPPARα 
and hPPARα receptors contribute to a species­
  specific PPARα­dependent metabolic response 
to DEHP.
Discussion
DEHP protects from diet-induced obesity 
in WT mice via hepatic PPARα activation. 
DEHP is the most widely used industrial plas­
ticizer, and human exposure to this pollutant 
is high through the daily use of polyvinyl chlo­
ride products (NTP­CERHR 2000). Mice fed 
either CD or HFD supplemented with DEHP 
were partially protected from diet­induced 
obesity because they gained 30% less weight 
than did their controls without modifying 
their feeding behavior. This reduced weight 
gain resulted solely from reduced fat mass and 
was associated with a metabolic improvement, 
which includes lower levels of tri  glycerides in 
the liver and the blood, smaller adipocytes, and 
enhanced glucose tolerance. Using a combina­
tion of metabolic phenotyping, metabo  lomics, 
gene expression profiling, and genetically engi­
neered mouse models, we could attribute this 
phenotype primarily to a PPARα­dependent 
activation of fatty acid catabolism in the liver. 
DEHP induced the expression of genes con­
trolling β­oxidation of fatty acids in the liver 
Figure 6. DEHP protects from obesity in mouse but not human models. PPARα WT and PPARα-humanized 
mice were fed HFD and exposed to vehicle or 500 mg/kg/day DEHP as described in Figure 2 (n = 5/group). 
(A) Body mass (BM) was measured after 13 weeks of treatment. (B–D) At the end of the treatment, epi-
WAT and liver masses were analyzed (B), and 3-hydroxyacyl-coenzyme A dehydrogenase (HAD) activity 
(C) and gene expression (D) were measured in the liver as described in Figure 4.
*p ≤ 0.05 compared with vehicle treatment. **p = 0.08. 
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as well as that of FGF­21, a novel PPARα tar­
get important for lipid oxidation and ketogen­
esis (Badman et al. 2007; Inagaki et al. 2007). 
We demonstrated that PPARα was required 
for the protective effect of DEHP by showing 
that both the protection from diet­induced 
obesity and the induction of oxidative genes in 
the liver were completely abolished in PPARα­
null mice. Although our results clearly demon­
strate DEHP­mediated metabolic interference 
via PPARα, other metabolic pathways—such 
as those driven by CAR (constitutive andros­
tane receptor) and Rev­Erbα (nuclear receptor 
subfamily 1, group D, member 1)—could also 
be involved (Eveillard et al. 2009). 
Unlike what has been hypothesized from 
the ability of MEHP to activate PPARγ and 
promote adipogenesis in cellular models 
(Bility et al. 2004; Feige et al. 2007; Grun and 
Blumberg 2007; Heindel 2003; Hurst and 
Waxman 2003), we found that DEHP expo­
sure does not cause PPARγ activation and fat 
accumulation in the adipose tissue of WT mice. 
The reasons for this observation remain unclear 
because MEHP has been detected as the major 
metabolite in the blood of rats treated with 
doses of DEHP in the same range as those used 
in the present study (Akingbemi et al. 2004). 
In those animals, circulating MEHP concen­
trations were around 10 µM (Akingbemi et al. 
2004), a level at which PPARγ can be activated 
by MEHP in cellular assays (Feige et al. 2007). 
Moreover, in our previous study (Feige et al. 
2007), the levels of MEHP in the blood were 
sufficient to induce the hepatic activation of 
PPARα, an activation that occurs at similar 
concentrations for PPARα and PPARγ. Thus, 
the most likely hypothesis is that MEHP can­
not enter adipocytes in sufficient concentra­
tions to activate PPARγ. 
DEHP exacerbates diet-induced obesity in 
a humanized PPARα mouse model. It is well 
established that DEHP is a potent inducer 
of hepato  cellular and peroxisome prolifera­
tion in rodents through PPARα activation 
by MEHP (Rusyn et al. 2006) and that 
these proliferative processes do not occur in 
humans after PPARα activation (Holden and 
Tugwood 1999). To overcome this limita­
tion and to evaluate the effects of DEHP in a 
model more relevant to humans, we adminis­
tered DEHP to mice humanized for PPARα 
(i.e., expressing the human PPARα receptor 
in the mPPARα null background) that do not 
exhibit hepatocellular proliferation but whose 
PPARα­dependent oxidative functions remain 
intact (Cheung et al. 2004; Yang et al. 2008). 
Strikingly, the metabolic actions of DEHP 
were abolished in this mouse model, which 
actually tended to be more sensitive to diet­
induced obesity than were untreated controls. 
This unexpected phenotype may relate to two 
main cellular defects. First, it is possible that 
hepatocellular proliferation and the resultant 
hepatomegaly itself are important metabolic 
contributors. Second, and more specifically, 
genes responsible for fatty acid oxidation are 
not up­regulated in the liver of DEHP­treated 
humanized PPARα mice, whereas they are 
markedly induced in response to synthetic 
PPARα agonists.
Although MEHP induced a similar trans­
activation of mPPARα and hPPARα in cel­
lular models, it actually induced stronger 
interactions with coactivators with the human 
receptor than with the mouse receptor in GST 
pull­downs. It is therefore surprising that the 
induction of PPARα target genes by DEHP 
exposure is blunted in PPARα­humanized 
mice. However, interactions with coregula­
tors depend highly on the promoter context 
(Guan et al. 2005), and the regulation of 
genes crucial to metabolic homeo  stasis could 
potentially involve promoter­specific interac­
tions with coregulators. Because activation 
of PPARα was recently reported to repress 
Let7C microRNA in WT but not in human­
ized PPARα mice (Shah et al. 2007; Yang 
et al. 2008), the blunted response to DEHP 
in PPARα­humanized mice may also reflect 
a dependency on this microRNA­mediated 
response. However, these hypotheses do not 
exclude the possibility that secondary MEHP 
metabolites could also play important roles in 
the metabolic actions of DEHP by differen­
tially activating hPPARα and mPPARα.
Considerations regarding the metabolic 
consequences of DEHP exposure in humans. 
The extrapolation of the action of DEHP 
from animal models to humans is definitely a 
complex issue that depends both on the rela­
tive levels of exposure and on the conservation 
of the underlying molecular mechanisms of 
action between species. Our studies involved 
relatively high levels of DEHP exposure, which 
were chosen according to previous reports of 
DEHP administration in rodents (David et al. 
1999; Lapinskas et al. 2005). These doses are 
2 to 3 orders of magnitude greater than esti­
mated human exposures when normalized to 
body mass (NTP­CERHR 2000). However, 
the extrapolation of biological observations 
from rodents to humans is not linear to body 
mass, and levels of mouse exposure similar to 
those used herein lead to plasmatic MEHP 
concentrations in the low micromolar range 
(Akingbemi et al. 2004). Moreover, individ­
uals requiring frequent blood transfusion or 
dialysis are subjected to repetitive acute expo­
sures to high levels of DEHP because of the 
leaching of the compound from plastic bags 
and tubing in direct contact with biological 
fluids. Under such circumstances, the plasma 
levels of MEHP can also reach the micromo­
lar range in humans (NTP­CERHR 2000), 
suggesting that the metabolic consequences of 
DEHP exposure described here may extend to 
humans. Thus, the most relevant observation 
is that DEHP slightly promotes weight gain 
in PPARα­humanized mice. Consistent with 
this observation, the urinary concentrations of 
phthalate metabolites have been recently posi­
tively correlated with obesity and insulin resis­
tance in humans (Hatch et al. 2008; Stahlhut 
et al. 2007). Our results clearly demonstrate 
that these effects are most likely not linked to 
activation of PPARγ and adipo  genesis in the 
adipose tissue but potentially to low hepatic 
oxidative metabolism.
Conclusion
Altogether, our results demonstrate that expo­
sure to the environmental pollutant DEHP has 
far­reaching metabolic consequences that rely 
on hepatic oxidative metabolism via PPARα 
activation. Furthermore, our study also high­
lights a species­specific relationship between 
exposure to DEHP and diet­induced obesity.
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